This is a summary of the European public assessment report (EPAR) for Votubia. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Votubia.
- What is Votubia?
Votubia is a medicine that contains the active substance everolimus. It is available as tablets (2.5, 5, 10 mg).
- What is Votubia used for?
Votubia is used to treat the following benign (non-cancerous) tumours caused by the genetic disease tuberous sclerosis:
- subependymal giant cell astrocytoma (SEGA), a benign tumour of the brain, where it is used in adults and children aged three years and above whose brain tumour cannot be surgically removed,
- renal angiomyolipoma, a benign tumour of the kidneys, where it is used in adults who are at risk of complications but who do not require immediate surgery.
Because the number of patients with tuberous sclerosis is low, the disease is considered ‘rare’, and Votubia was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 4 August 2010.
The medicine can only be obtained with a prescription.
- How is Votubia used?
Votubia treatment should be started by a doctor experienced in treating tuberous sclerosis and in drug monitoring.
Votubia is taken by mouth once a day at the same time every day, consistently either with or without food.
For SEGA, the starting dose depends on the body surface area (calculated using the patient’s height and weight), but the doctor will adjust the dose based on the patient’s blood levels of the medicine and how well the patient tolerates the medicine.
In patients with renal angiomyolipoma, the recommended dose is 10 mg once a day. In case patients experience severe side effects the doctor may need to reduce the dose or interrupt treatment temporarily.
Patients with mild or moderate impairment of liver function should be started at a lower dose. Votubia is not recommended for patients with SEGA and severe impairment of liver function. For patients with renal angiomyolipoma and severe impairment of liver function Votubia is only recommended if the desired benefit outweighs the risk.
- How does Votubia work?
The active substance in Votubia, everolimus, is an anti-tumour medicine that acts by blocking an enzyme called ‘mammalian target of rapamycin’ (mTOR), which has increased activity in tumour cells of patients with SEGA or renal angiomyolipoma. In the body, everolimus first attaches to a protein called FKBP-12 that is found inside cells to make a ‘complex’. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Votubia prevents the division of tumour cells and reduces their blood supply.
- How has Votubia been studied?
In SEGA caused by tuberous sclerosis, Votubia has been studied in one main study involving 28 adults and children aged three years and above. The main measure of effectiveness was based on how much the patient’s main brain tumour shrank after six months of treatment.
In renal angiomyolipoma caused by tuberous sclerosis, Votubia has been compared with placebo (a dummy treatment) in one study involving 118 adults. The main measure of effectiveness was the proportion of patients who responded to treatment and whose kidney tumour shrank by at least half.
- What benefit has Votubia shown during the studies?
Votubia was shown to be effective at treating patients with SEGA and renal angiomyolipoma by shrinking the volume of the tumours. In patients with SEGA, the main brain tumour shrank by half in approximately 30% of patients and by about a third in around 70% of patients. In patients with renal angiomyolipoma, the kidney tumour shrank by at least half in 42% of patients (33 out of 79 patients) treated with Votubia, compared with none of the 39 patients who received placebo.
- What is the risk associated with Votubia?
The most common side effects (seen in more than 1 in 10 patients) in studies with Votubia are infections, stomatitis (inflammation of the lining of the mouth) and increased blood levels of cholesterol.For the full list of all side effects reported with Votubia, see the package leaflet.
Votubia must not be used in people who are hypersensitive (allergic) to everolimus, to related medicines such as sirolimus and temsirolimus or to any of the other ingredients.
- Why has Votubia been approved?
The CHMP noted that Votubia has been shown to reduce the size of the brain tumours and that this is expected to reduce the signs and symptoms of SEGA such as seizures, hydrocephalus (accumulation of fluid in the brain), and increased pressure within the brain. Although surgery remains the standard treatment for this condition, Votubia is expected to benefit patients whose tumour cannot be operated on. Votubia has also been shown to reduce the size of kidney tumours in patients with renal angiomyolipoma. The side effects of the medicine were considered to be manageable and were generally mild or moderate. The CHMP therefore concluded that the benefits of Votubia outweigh its risks and recommended that it be given marketing authorisation.
Votubia has been given ‘conditional approval’. This means that there is more evidence to come about the medicine, in particular its long-term effects. Every year, the European Medicines Agency will review any new information that may become available and this summary will be updated as necessary.
- What information is still awaited for Votubia?
The company that makes Votubia will provide more study results on the long-term effects of the medicine, the duration of the response to treatment and how the medicine is handled in the body.
- Other information about Votubia
The European Commission granted a conditional marketing authorisation valid throughout the European Union for Votubia on 02 September 2010.
For more information about treatment with Votubia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
|Name||Language||First published||Last updated|
|Votubia : EPAR - Summary for the public||BG = bălgarski||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||ES = español||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||CS = čeština||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||DA = dansk||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||DE = Deutsch||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||ET = eesti keel||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||EL = elliniká||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||EN = English||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||FR = français||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||IT = italiano||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||LV = latviešu valoda||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||LT = lietuvių kalba||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||HU = magyar||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||MT = Malti||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||NL = Nederlands||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||PL = polski||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||PT = português||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||RO = română||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||SK = slovenčina||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||SL = slovenščina||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||FI = suomi||19/09/2011||03/12/2012|
|Votubia : EPAR - Summary for the public||SV = svenska||19/09/2011||03/12/2012|
This EPAR was last updated on 25/01/2013 .
19/12/2012 Votubia -EMEA/H/C/002311 -IB/0012
|Name||Language||First published||Last updated|
|Votubia : EPAR - Product Information||BG = bălgarski||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||ES = español||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||CS = čeština||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||DA = dansk||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||DE = Deutsch||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||ET = eesti keel||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||EL = elliniká||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||EN = English||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||FR = français||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||IT = italiano||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||LV = latviešu valoda||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||LT = lietuvių kalba||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||HU = magyar||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||MT = Malti||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||NL = Nederlands||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||PL = polski||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||PT = português||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||RO = română||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||SK = slovenčina||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||SL = slovenščina||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||FI = suomi||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||SV = svenska||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||IS = Islenska||19/09/2011||25/01/2013|
|Votubia : EPAR - Product Information||NO = Norsk||19/09/2011||25/01/2013|
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Votubia is indicated for the treatment of patients aged 3 years and older with subependymal giant-cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery.
The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease-related symptoms, has not been demonstrated.
Changes since initial authorisation of medicine
|Name||Language||First published||Last updated|
|Votubia : EPAR - Procedural steps taken and scientific information after authorisation||(English only)||23/02/2012||25/01/2013|
|CHMP post-authorisation summary of positive opinion for Votubia||(English only)||21/09/2012|
|Votubia-H-C-2311-II-04 : EPAR - Assessment Report - Variation||(English only)||03/12/2012|
Initial marketing-authorisation documents
This medicine is approved for use in the European Union